Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1

          -  Cardiac parameters within the following range: corrected QT interval (QTc intervals
             corrected using Fridericia's formula [QTcF]) less than or equal to (<=)480
             milliseconds based on the average of triplicate assessments performed no more than 5
             minutes apart (plus minus [+-]3 minutes)

          -  Women of childbearing potential must have a negative highly sensitive serum (Beta
             human chorionic gonadotropin) at screening and prior to the first dose of study drug,
             and until 30 days after the last dose

          -  In addition to the user-independent, highly effective method of contraception, a male
             or female condom with or without spermicide is required, example, condom with
             spermicidal foam/gel/film/cream/suppository. Male condom and female condom should not
             be used together (due to risk of failure with friction)

          -  Men must wear a condom when engaging in any activity that allows for passage of
             ejaculate to another person. Male participants should also be advised of the benefit
             for a female partner to use a highly effective method of contraception as condom may
             break or leak

        Exclusion Criteria:

          -  Known active central nervous system (CNS) involvement for dose escalation and specific
             expansion cohorts as determined by the study evaluation team (SET)

          -  Prior solid-organ transplantation

          -  Either of the following: a) Received an autologous stem cell transplant less than or
             equal to (<=)3 months before the first dose of study drug. b) Prior treatment with
             allogenic stem cell transplant <=6 months before the first dose of study drug, has
             evidence of graft versus host disease, or requires immunosuppressant therapy for graft
             versus host disease within the last 4 weeks

          -  History of malignancy (other than the disease under study in the cohort to which the
             participant is assigned) within 1 year prior to the first administration of study
             drug. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in
             situ of the cervix, or malignancy which in the opinion of the investigator, with
             concurrence with the sponsor's medical monitor, is considered cured with minimal risk
             of recurrence within 1 year before the first dose of study drug. Concomitant
             malignancies that are unlikely to progress and/or preclude evaluation of study
             endpoints may be allowed after discussion with the Study Responsible Physician

          -  Prior treatment with a mucosa-associated lymphoid tissue lymphoma translocation
             protein 1 (MALT1) inhibitor